StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
603579.SS$19.55+2.79%
Fair $19.55+0.0%

603579.SS

Shanghai Rongtai Health Technology Corporation Limited

Consumer Cyclical / LeisureShanghai

$19.55

+0.53 (+2.79%)

Fairly Valued+0.0%Fair Value $19.55Fund rank 31/100 · Data gapFallback financials|
SA 40/C
F-Score: 5/9
Declining Revenue

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 32% · confianza 25%

FCF escenarios

weak_data · normalized FCF $62.9M · quality 61.7/100

Data gap 31/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 42/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

40/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 3 consecutive years
Thesis & Journal · 603579.SSLocal privado en este navegador · Shanghai Rongtai Health Technology Corporation Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$3.9B

P/E

21.0x

↑

EV/EBITDA

12.0x

↑

ROE

5.4%

↑

Gross Margin

30.7%

↑

Debt/Equity

0.06

↓
52-Week Range$20
$19$45

TradingView lightweight chart

603579.SS price, volumen y niveles de valoración

Último $19.55Periodo -39.2%
Fair value: $19.55

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-7.8%

FCF CAGR

-22.7%

FCF margin

4.0%

FCF / Net income

0.42x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.57B · net income $150.7M · FCF $62.9M

2022-FY → 2025-FY

Gross margin

30.7%+4.2% pts

Operating margin

6.3%-2.2% pts

Net margin

9.6%+1.4% pts

FCF margin

4.0%-2.8% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.57B$1.57B$1.60B$1.86B$2.00B
Net Income$150.7M$150.7M$191.9M$202.7M$164.2M
EBITDA$260.0M$260.0M$272.9M$317.6M$267.1M
EPS0.830.830.971.170.95
Gross Margin30.7%30.7%31.7%30.5%26.5%
Operating Margin6.3%6.3%10.3%11.6%8.5%
Net Margin9.6%9.6%12.0%10.9%8.2%
Balance Sheet
Debt/Equity0.060.060.530.380.54
Current Ratio2.852.85———
Cash Flow
Free Cash Flow$62.9M$62.9M$17.1M$254.7M$136.1M
Returns
ROE5.4%5.4%9.5%10.3%8.8%
Valuation
P/E21.0221.0214.2418.7421.67
EV/EBITDA11.9911.9912.129.9812.13
P/B1.271.271.361.931.91
Growth & Yield
Revenue Growth-1.5%-1.5%-13.9%-7.5%—
EPS Growth-14.4%-14.4%-17.1%23.7%—
Dividend Yield3.3%3.3%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

27.9%

muy exigente

EPS terminal req.

$1.73

Spread vs growth

-42.3%

5Y implied EPS CAGR

20.4%

exigente

EPS terminal req.

$2.10

Spread vs growth

-34.8%

10Y implied EPS CAGR

15.1%

exigente

EPS terminal req.

$3.38

Spread vs growth

-29.5%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -22.0%

Total return

-22.0%

Start / end P/E

27.0x → 23.6x

EPS bridge

0.97 → 0.83

Residual

+1.8%

EPS growth-14.4%
Multiple rerating-12.8%
Dividend+3.3%
Residual / FX / buybacks / cross-term+1.8%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.